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INTRODUCTION
Do we need an observational study on the manage-
ment of anemia in transplant patients?
In contrast to the situation for patients on dialysis, there are
only limited data available regarding the management of ane-
mia in long-term kidney-transplanted patients (1). 
It can be anticipated that a substantial part of these transplant
patients fall in the chronic kidney disease (CKD) stages 3, 4 and
5, and therefore that some degree of renal anemia is prevalent. 
The Transplant European Survey on Anemia Management
(TRESAM) (2) revealed that more than one third of the trans-
plant patients had some degree of anemia. It is quite likely
that, besides the renal factors causing anemia (3), other fac-
tors also, such as chronic inflammation and the use of certain
immunosuppressive agents, contribute to the enhanced risk
of anemia in these patients (4). 
The registration of patients planned by the QUEST (QUality
European STudies) project would thus deliver new information
on the general performance of renal function in long-term trans-
plant patients and also on the specific domain of the impact of
CKD on anemia in transplant patients, and its management.
Although the data on the need for, and the use of, erythro-
poiesis-stimulating agents (ESAs) in transplant patients are
scarce (1), it would not come as a surprise to see a higher
degree of underachievement of anemia management in this
patient group compared with other clinical settings for
patients with CKD. 
To start with, many physicians and patients are reluctant to
admit that the renal function of a graft is suboptimal, espe-
cially if it is declining over time. Talking about starting treat-
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ment with ESAs might ring a bell in the patient’s mind that
“something is going wrong”, and it is not unlikely that both
patients and physicians will try to delay this moment as
long as possible. It has been described that in anemic
transplant patients, only a minority receive ESAs (2, 5). 
Second, iron management might be more problematic in
this patient group, as easy access to intravenous iron is
not available as it is in dialysis patients, which might also
lead to incomplete correction of anemia. Molnar et al found
(5) that iron deficiency was an important predictor of ane-
mia in renal transplant patients, even after correction for
kidney function and chronic inflammation. Winkelmayer et
al (6) found that the percentage of hypochromic red blood
cells rather than anemia per se was related to mortality and
graft loss. Third, it might be that financial reimbursement
for ESAs is cumbersome in some regions or countries. 
Anemia is related to cardiovascular comorbidity and other
bad outcomes in CKD patients. In addition, the available
evidence indicates that anemia is an early indicator of bad
prognosis, both for graft and patient survival (7) and also
for cardiovascular morbidity (8) in transplant patients.
A well-performed observational study is thus urgently need-
ed to obtain more information on the management of anemia
in renal transplant patients, and its relation with outcome.
STUDY PROTOCOL FOR PREVALENCE
AND MANAGEMENT OF ANEMIA IN RENAL
TRANSPLANT PATIENTS: A MULTICENTER
CROSS-SECTIONAL EUROPEAN STUDY
Introduction
Anemia is a common and well-recognized problem in
patients with CKD. Over the last 2 decades, treatment of
renal anemia has been substantially improved by the intro-
duction of ESAs. Data on the management of anemia in
transplant patients are scarce, and the available evidence
seems to indicate that transplant patients, despite being
in at least CKD stage 3, are mostly not considered as CKD
patients. Physicians have a low awareness of renal ane-
mia in these patients and/or are reluctant to start treat-
ment with ESAs.
Renal transplant patients have several concomitant and
cumulative reasons for being anemic, and it is not surpris-
ing that the prevalence of anemia in transplant patients is
reported to be quite high. However, prevalence and best
treatment of anemia in renal transplant patients has not
yet been fully elucidated on a large scale. In particular, lit-
tle is known about causes of ESA hyporesponsiveness in
this setting. In view of the potential effect of anemia on the
outcome of both patient and graft survival, and many
deleterious posttransplant factors (medications, chronic
inflammation, declining renal function etc) the present
investigation could give important new insights. 
Aim of the project
1. Identify the relative contribution of the different factors
that hamper optimal correction of anemia in renal
transplant patients by determining
- the prevalence and distribution of CKD stages 3, 4
and 5 in a large European renal transplant patient
population;
- the prevalence and distribution of anemia in a large
European renal transplant patient population; 
- the degree of anemia correction achieved and
dosage patterns of ESAs;
- the prevalence of ESA hyporesponsiveness (i.e.,
>300 U/kg per week) (considered as a continuous
and as a categorical variable) and its underlying
causes; 
- the factors that may explain differences in anemia
correction and/or ESA hyporesponsiveness at a
national, regional and/or center level.
2. Set up an instrument that will allow us to improve anemia
management at the individual patient and center level.
It is anticipated that, as part of a quality improvement pro-
gram, the return of the results to the participating centers
will also allow each of them to optimize their anemia man-
agement at the levels of individual patient and center care.
Therefore, the same evaluation will be conducted after 1
year in the same participating centers.
Study design
This project is a cross-sectional study of all renal trans-
plant patients followed in the participating units and will
register the following:
- demographic, clinical and hematologic data; 
- renal function (measured creatinine clearance and/or
estimated glomerular filtration rate [eGFR]);
- immunosuppressive regimens;
- use of ESAs; 
- iron management and administration;
- other parameters potentially related to ESA hypore-
sponsiveness.
544
Van Biesen et al: Anemia in renal transplantation
After 12 months, the same evaluation will be repeated in
the same centers according to the same inclusion and
exclusion criteria.
Center and patient inclusion criteria
Countries and centers to be included in the study will be
selected aiming at a wide geographical coverage that is
balanced across Europe, and starting with those countries
represented in the working group. The target number for
inclusion of patients is 3,500. 
The working group members will act as study counsellors
at the national level and verify the time schedule at the
participating units. 
In addition, a part-time study coordinator and data man-
ager will be hired.
Participating centers will receive 10 euros per completed
patient file.
All centers which participate should include all surviving
renal transplant patients at the time of their last visit dur-
ing the preceding 12 months.
Patients should have undergone a transplant at least 1
year previously, to avoid the interference of acute prob-
lems related to the act of transplantation.
Local ethics committee approval and patient informed con-
sent forms may be requested depending on the national
and/or local regulations. In cases where an informed con-
sent form is mandatory at the local level, the number of
patients refusing to participate should not exceed 10% of
the total number of treated patients. If this percentage is
exceeded, another center should be asked to participate. 
Study protocol
Parameters to register:





- Height and weight to calculate Body Mass Index
(BMI) and Body Surface Area (BSA) adjusted GFR
- Type of underlying renal disease (according to
EDTA Registry coding)
- Diabetes as cause of renal failure: yes/no
- Posttransplant-related diabetes: yes/no
- Time since transplant: months
- Type of transplant: living or cadaver
- Number of present transplant: first, second …
2. Biological and clinical data 
- Hemoglobin (Hb)
- Reticulocyte count 
- Iron store parameters: ferritin, transferrin saturation
- Renal function (either measured creatinine clear-
ance and/or estimated GFR based on the IDMS
(Isotope Dilution Mass Spectrometry) traceable
simplified Modification of Diet in Renal Disease
[MDRD] formula)
- Serum albumin
- C-reactive protein (CRP)
- Intact parathormone (PTH) level
- Serologic hepatitis B and C status 
- Aggravating clinical factors during the preceding 3
months: infection, malignancy, episodes of bleed-
ing, surgery, hospitalization …
- Delayed graft function after transplant: yes/no
(need for dialysis)
3. Therapeutic data 
- Immunosuppression: daily doses at the time of Hb
determination
- Use of ESA: yes/no
1. agent: epoetin-alpha, epoetin-beta, darbepoetin,
other … 
2. total administered dose during the 4 weeks pre-
ceding the biological control (raw units/weights;
a conversion factor for darbepoetin-alpha will be
applied centrally)
3. administration route: subcutaneous or intra-
venous
4. administration frequency: days/month …
5. start of ESA: <3 months, between 3-6 months,
>6 months before data collection
6. time after transplant, creatinine level (or eGFR),
Hb concentration at start of ESA 
- Iron administration (in the extended data set):
yes/no
1. agent: saccharate, dextran, gluconate, other …
2. total administered dose over the 4 weeks pre-
ceding the biological control
3. administration route: intravenous vs. peroral
4. administration frequency: days/month, on
demand
- (Oral) anticoagulants: yes/no
- Platelet inhibitors: yes/no
- Angiotensin-converting enzyme inhibitors and/or
sartanes: yes/no
B. Center data
1. Transplant center policy 
545
JNEPHROL 2007; 20: 543-546
- Recommended type and mode of ESA administration
- Type of guidelines followed
- Type of iron storage parameters and dosage; iron
administration and policy in interval prior to serum
iron parameter sampling
- Management of anemia parameters on a daily
basis: nephrologist, transplant consultant nurse,
dedicated nurse
2. Use of management software tools and/or database
3. National/regional policy for ESA prescription 
4. National/regional policy for ESA reimbursement
Statistical analysis
Statistical analysis will include 
1. descriptive analysis of the data, at the individual cen-
ter, country and European levels (mean and/or median,
with 25th and 75th percentiles, as appropriate);
2. comparisons in relevant subgroups according to sex,
country, cadaveric vs. living graft, delayed graft func-
tion, immunosuppressive regimen, ESA agent, admin-
istration route of ESA etc. These analyses will be per-
formed by t-test, Mann-Whitney test or 1-way ANOVA,
as applicable ;
3. univariate and multivariate regression analysis of differ-
ent continuous variables (Hb, ESA dose, age, months
on dialysis, months after transplant, iron parameters,
CRP, renal function, PTH) with ESA dose, and Hb lev-
els achieved.
To avoid interference with “loading dose” problems,
patients treated with ESA for less than 6 months will be
analyzed separately.
For all statistical investigations and their results, it will be
kept in mind that these should be considered as hypotheses
generating associations, and that these may not be causal.
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